Mauro Iannopollo

612 total citations
10 papers, 454 citations indexed

About

Mauro Iannopollo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Mauro Iannopollo has authored 10 papers receiving a total of 454 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in Mauro Iannopollo's work include Colorectal Cancer Treatments and Studies (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Mauro Iannopollo is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Mauro Iannopollo collaborates with scholars based in Italy and United States. Mauro Iannopollo's co-authors include Cinzia Orlandini, Sergio Ricci, Mario Del Tacca, Romano Danesi, Valentina Mey, Ugo Boggi, Generoso Bevilacqua, Marco Del Chiaro, Daniela Campani and Elisa Giovannetti and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Mauro Iannopollo

9 papers receiving 448 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mauro Iannopollo Italy 7 306 133 111 109 83 10 454
Isaya Hashimoto Japan 9 249 0.8× 181 1.4× 83 0.7× 70 0.6× 63 0.8× 32 494
Monica Capozzi Italy 11 239 0.8× 133 1.0× 94 0.8× 32 0.3× 72 0.9× 22 434
Takako Nirei Japan 9 284 0.9× 97 0.7× 103 0.9× 85 0.8× 42 0.5× 13 435
Jing‐Yun Wen China 13 255 0.8× 172 1.3× 199 1.8× 67 0.6× 81 1.0× 36 594
Simon Wabitsch Germany 14 208 0.7× 71 0.5× 55 0.5× 182 1.7× 115 1.4× 30 522
Alexander B. Sibley United States 12 171 0.6× 124 0.9× 71 0.6× 21 0.2× 80 1.0× 27 393
Yasuhiro Arakawa Japan 11 159 0.5× 150 1.1× 94 0.8× 90 0.8× 86 1.0× 37 380
Angel Qin United States 12 343 1.1× 178 1.3× 122 1.1× 45 0.4× 201 2.4× 33 561
Haruhito Sakata Japan 13 154 0.5× 251 1.9× 83 0.7× 81 0.7× 84 1.0× 34 483
Connie W. C. Hui Hong Kong 11 129 0.4× 157 1.2× 63 0.6× 54 0.5× 154 1.9× 21 389

Countries citing papers authored by Mauro Iannopollo

Since Specialization
Citations

This map shows the geographic impact of Mauro Iannopollo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mauro Iannopollo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mauro Iannopollo more than expected).

Fields of papers citing papers by Mauro Iannopollo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mauro Iannopollo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mauro Iannopollo. The network helps show where Mauro Iannopollo may publish in the future.

Co-authorship network of co-authors of Mauro Iannopollo

This figure shows the co-authorship network connecting the top 25 collaborators of Mauro Iannopollo. A scholar is included among the top collaborators of Mauro Iannopollo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mauro Iannopollo. Mauro Iannopollo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
2.
Lastraioli, Elena, Alessandra Bettiol, Jessica Iorio, et al.. (2023). Evaluation of RAS Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients. Cells. 12(11). 1458–1458. 4 indexed citations
3.
Iannopollo, Mauro, et al.. (2021). Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review. Life. 11(10). 1036–1036. 7 indexed citations
4.
Petrini, Iacopo, Monica Lencioni, Mauro Iannopollo, et al.. (2011). Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology. 69(3). 773–780. 57 indexed citations
5.
Petrini, Iacopo, Monica Lencioni, Mauro Iannopollo, et al.. (2009). A phase II (PhII) trial of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (c.i.) in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary data. Journal of Clinical Oncology. 27(15_suppl). 4592–4592. 8 indexed citations
6.
Paolo, Antonello Di, Monica Lencioni, Samantha Di Donato, et al.. (2008). 5-Fluorouracil Pharmacokinetics Predicts Disease-free Survival in Patients Administered Adjuvant Chemotherapy for Colorectal Cancer. Clinical Cancer Research. 14(9). 2749–2755. 46 indexed citations
7.
Ballatori, Enzo, Fausto Roila, Benedetta Ruggeri, et al.. (2006). The cost of chemotherapy-induced nausea and vomiting in Italy. Supportive Care in Cancer. 15(1). 31–38. 25 indexed citations
8.
Giovannetti, Elisa, Mario Del Tacca, Valentina Mey, et al.. (2006). Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with Gemcitabine. Cancer Research. 66(7). 3928–3935. 278 indexed citations
9.
Ricci, Sergio, Luca Galli, Mauro Iannopollo, et al.. (2002). Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum‐based regimens. Cancer. 95(7). 1444–1450. 28 indexed citations
10.
Tibaldi, Carmelo, Stefano Ricci, Francesca Russo, et al.. (2001). Chemotherapy with gemcitabine in elderly patients (or in patients not candidate for a cisplatin regimen) with advanced NSCLC: a multicenter phase II study. European Journal of Cancer. 37. S59–S59. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026